References
- National Cancer Institute. SEER cancer statistics review 1975-2007 (updated 8 October 2010). Available from: http://seer.cancer.gov/csr/1975_2007/index.html.
- Delgado J, Briones J, Sierra J. Emerging therapies for patients with advanced chronic lymphocytic leukaemia. Blood Rev 2009;23: 217–224.
- Keating MJ, O'Brien S, Kontoyiannis D, . Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002;43:1755–1762.
- National Comprehensive Cancer Network. NCCN clinical practice guidelines oncology: non-Hodgkin's lymphomas, 2010 V.1. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
- Eichhorst B, Hallek M, Dreyling M; ESMO Guidelines Working Group. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl. 5):v162–v164.
- Tam CS, O'Brien S, Lerner S, . The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 2007;48:1931–1939.
- Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008:450–456.
- Chang DH, Liu N, Klimek V, . Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide:therapeutic implications. Blood 2006;108:618–621.
- Ramsay AG, Johnson AJ, Lee AM, . Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427–2437.
- Wu L, Adams M, Carter T, . Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 + tumor cells. Clin Cancer Res 2008;14:4650–4657.
- Chanan-Khan A, Miller KC, Musial L, . Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia:results of a phase II study. J Clin Oncol 2006;24:5343–5349.
- Ferrajoli A, Lee BN, Schlette EJ, . Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291–5297.
- Moutouh-de Parseval LA, Weiss L, DeLap RJ, . Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 2007;25:5047.
- Cheson BD, Bennett JM, Grever M, . National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.
- Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3–11.
- Cheson BD, Frame JN, Vena D, . Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 1998;16:2313–2320.
- Jensen M, Winkler U, Manzke O, . Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998;77:89–91.
- Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999;62:247–250.
- Byrd JC, Lin TS, Dalton JT, . Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399–404.
- Chanan-Khan A, Miller KC, Lawrence D, . Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011;117:2127–2135.
- Chanan-Khan A, Miller KC, Whitworth A, . Clinical activity of lenalidomide in relapsed or refractory chronic lymphocytic leukemia (CLL) patients: updated results of a phase II clinical trial. Leuk Lymphoma 2007;48(Suppl. 1): Abstract S166.